

Patient Number	Treatment Cohort	Radiation Regimen	Chemotherapy Prior to RT	Chemotherapy Concurrent with RT
1	Chemo/RT	5400 cGy, unclear fractionation	5-FU	5-FU
2	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	FOLFIRINOX	Gemcitabine
3	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	FOLFIRINOX	Gemcitabine
4	Chemo/RT	4860 cGy, unclear fractionation	Gemcitabine	Gemcitabine
5	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	FOLFIRINOX	Gemcitabine
6	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	FOLFIRINOX	Gemcitabine
7	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	FOLFIRINOX	Gemcitabine
8	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	Gemcitabine + Oxaliplatin	Capecitabine
9	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	Gemcitabine	Gemcitabine
10	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	FOLFIRINOX	Gemcitabine
11	Chemo/RT	3240 cGy, 180 cGy daily, 18 fractions	Gemcitabine/Abraxane	Gemcitabine/Abraxane
12	Chemo/RT	5745 cGy, 383 cGy daily, 15 fractions	Gemcitabine/Abraxane	Gemcitabine/Abraxane
13	Chemo/RT	5500 cGy, 220 cGy daily, 25 fractions	FOLFIRINOX → Capecitabine	Capecitabine
14	Chemo/RT	5040 cGy, 180 cGy daily, 28 fractions	Gemcitabine	Gemcitabine
15	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	FOLFIRINOX	Capecitabine
16	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	Gemcitabine/Abraxane	Gemcitabine/Abraxane
17	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	FOLFIRINOX → Gemcitabine/Abraxane	Capecitabine
18	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	Gemcitabine/Abraxane	Gemcitabine/Abraxane
19	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	Gemcitabine/Abraxane	Gemcitabine/Abraxane
20	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	Gemcitabine/Abraxane	Gemcitabine/Abraxane
21	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	Cisplatin + Gemcitabine → FOLFIRINOX	Capecitabine
22	Chemo/SBRT	6750 cGy, 450 cGy daily, 15 fractions	Gemcitabine/Abraxane	Capecitabine

Supplementary Table S1: Treatment History of PDAC Patients in Figure 1

Detailed RT dose and fractionation regimen and chemotherapy treatment prior to RT and concurrent with RT for patients used in **Figure 1**.